Detection of Endotoxin in Plasma and Ascitic Fluid of Patients with Cirrhosis: Its Clinical Significance

Tarao, Kazuo; So, Kooi; Moroi, T; Ikeuchi, Takao; Suyama, Takashi

doi:10.1016/s0016-5085(19)32137-7

Cited by 128 publications

(33 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The significance of increased endotoxin levels during cirrhosis has been described (Navasa et al, 1998;Tarao et al, 1977). In contrast, the endotoxin concentrations in cirrhotic patients in our study were not higher than those in the other ALD subgroups.…”

Section: Discussioncontrasting

confidence: 74%

Endotoxin, Endotoxin‐Neutralizing‐Capacity, sCD14, sICAM‐1, and Cytokines in Patients With Various Degrees of Alcoholic Liver Disease

Urbaschek

McCuskey

Rudi

et al. 2001

Alcoholism Clin & Exp Res

View full text Add to dashboard Cite

show abstract

Section: Discussioncontrasting

confidence: 74%

Endotoxin, Endotoxin‐Neutralizing‐Capacity, sCD14, sICAM‐1, and Cytokines in Patients With Various Degrees of Alcoholic Liver Disease

Urbaschek

McCuskey

Rudi

et al. 2001

Alcoholism Clin & Exp Res

View full text Add to dashboard Cite

show abstract

“…As most LPS circulates bound to plasma proteins, LPS is not measured using the standard limulus amoebocyte lysate (LAL) which can only detect free molecules. On the other hand, bound LPS can be measured and, in alcoholic steatohepatitis, has been found to be 6-10 fold greater than in healthy subjects [80]. To estimate bound LPS we measured lipopolysaccharide significantly higher than those of NASH patients (P = 0.0037 and 0.0195, respectively).…”

Section: Discussionmentioning

confidence: 96%

Small Intestinal Bacterial Overgrowth in Nonalcoholic Steatohepatitis: Association with Toll-Like Receptor 4 Expression and Plasma Levels of Interleukin 8

et al. 2010

View full text Add to dashboard Cite

show abstract

“…Der bei PD bessere Erhalt der Nierenrestfunktion sollte auch für Patienten mit Leberzirrhose von Vorteil sein. Auch wird diskutiert, dass Endotoxine, die bei Leberzirrhose im Aszites akkumulieren[2], durch PD-Therapie besser eliminiert werden. Die PD bietet für Dialysezentren die Möglichkeit, durch eine "Auslagerung" von Patienten mit Hepatitis B oder C das Infektionsrisiko innerhalb des Zentrums zu reduzieren.…”

unclassified

Peritonealdialyse bei Patienten mit Leberzirrhose und/oder Aszites

Paul

2005

Wien Klin Wochenschr

View full text Add to dashboard Cite

In older textbooks the use of peritoneal dialysis (PD) in patients with liver cirrhosis and/or ascites was contraindicated. Only a small number of papers have focused on this problem and they mainly consist of case reports and retrospective studies of small numbers of patients. In addition, most nephrologists' experience of performing PD in patients with liver diseases is rather limited. Nevertheless, for these patients PD offers a wide range of advantages, such as a simplified ascites management, since repeated abdominal punctures become unnecessary. Furthermore, because of continuous peritoneal ultrafiltration, hemodynamic tolerance during PD is significantly better than in hemodialysis and results in a markedly lower frequency of hypotensive episodes. The risk of nosocomial infection with hepatitis B or C viruses can also be reduced by treating these patients with home PD. Although some authors suggest that PD patients with liver cirrhosis have an especially increased risk of Gram-negative peritonitis, currently available data show controversial results. There is also little information in the literature on the impact of increased peritoneal protein loss on malnutrition and outcome of these patients. Nevertheless, recent studies have shown that protein loss into the peritoneal cavity in PD patients with liver cirrhosis is high only initially, stabilizing at a lower level in the further course of treatment. In conclusion, in patients with end-stage renal disease suffering from liver cirrhosis and/or ascites, PD can be considered as a good or adequate treatment option.

show abstract

Detection of Endotoxin in Plasma and Ascitic Fluid of Patients with Cirrhosis: Its Clinical Significance

Cited by 128 publications

References 18 publications

Endotoxin, Endotoxin‐Neutralizing‐Capacity, sCD14, sICAM‐1, and Cytokines in Patients With Various Degrees of Alcoholic Liver Disease

Endotoxin, Endotoxin‐Neutralizing‐Capacity, sCD14, sICAM‐1, and Cytokines in Patients With Various Degrees of Alcoholic Liver Disease

Small Intestinal Bacterial Overgrowth in Nonalcoholic Steatohepatitis: Association with Toll-Like Receptor 4 Expression and Plasma Levels of Interleukin 8

Peritonealdialyse bei Patienten mit Leberzirrhose und/oder Aszites

Contact Info

Product

Resources

About